Multivariate Cox proportional hazard analysis of OS and PFS in the LRF CLL4 patients
| Variable . | Overall survival . | Progression-free survival . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| NOTCH1 | 1.58 | 1.05-2.38 | .03 | 1.29 | 0.87-1.90 | .21 |
| SF3B1 | 1.52 | 1.10-2.12 | .01 | 1.31 | 0.97-1.78 | .08 |
| Age | 1.05 | 1.03-1.07 | < .001 | 0.99 | 0.98-1.01 | .29 |
| Sex | 0.72 | 0.53-0.99 | .04 | 0.82 | 0.63-1.08 | .15 |
| Binet stage (A vs B/C) | 1.45 | 1.02-2.04 | .04 | 1.02 | 0.77-1.36 | .90 |
| del(11q) | 1.39 | 1.04-1.87 | .03 | 1.61 | 1.22-2.11 | .001 |
| IGHV unmutated | 1.85 | 1.38-2.50 | < .001 | 1.86 | 1.43-2.42 | < .001 |
| TP53 del/mut | 2.48 | 1.50-4.08 | < .001 | 2.09 | 1.29-3.37 | .003 |
| LRF CLL4 arm (Chl vs FDR/FC) | 1.01 | 0.78-1.30 | .97 | 0.50 | 0.40-0.63 | < .001 |
| Variable . | Overall survival . | Progression-free survival . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| NOTCH1 | 1.58 | 1.05-2.38 | .03 | 1.29 | 0.87-1.90 | .21 |
| SF3B1 | 1.52 | 1.10-2.12 | .01 | 1.31 | 0.97-1.78 | .08 |
| Age | 1.05 | 1.03-1.07 | < .001 | 0.99 | 0.98-1.01 | .29 |
| Sex | 0.72 | 0.53-0.99 | .04 | 0.82 | 0.63-1.08 | .15 |
| Binet stage (A vs B/C) | 1.45 | 1.02-2.04 | .04 | 1.02 | 0.77-1.36 | .90 |
| del(11q) | 1.39 | 1.04-1.87 | .03 | 1.61 | 1.22-2.11 | .001 |
| IGHV unmutated | 1.85 | 1.38-2.50 | < .001 | 1.86 | 1.43-2.42 | < .001 |
| TP53 del/mut | 2.48 | 1.50-4.08 | < .001 | 2.09 | 1.29-3.37 | .003 |
| LRF CLL4 arm (Chl vs FDR/FC) | 1.01 | 0.78-1.30 | .97 | 0.50 | 0.40-0.63 | < .001 |
OS Multivariate: 330 cases with 244 events; 164 cases with missing data. PFS Multivariate: 330 cases with 306 events; 164 cases with missing data. TP53 abnormalities defined by deletion and/or mutation (del/mut).